Short Interest in Opus Genetics, Inc. (NASDAQ:IRD) Drops By 30.7%

Opus Genetics, Inc. (NASDAQ:IRD) saw a significant decline in short interest in January. As of January 30th, there was short interest totaling 664,201 shares, a decline of 30.7% from the January 15th total of 957,806 shares. Currently, 1.0% of the company’s stock are short sold. Based on an average daily volume of 924,259 shares, the short-interest ratio is presently 0.7 days. Based on an average daily volume of 924,259 shares, the short-interest ratio is presently 0.7 days. Currently, 1.0% of the company’s stock are short sold.

Opus Genetics News Summary

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: Lifesci Capital upgraded IRD to “Strong‑Buy” and published quarterly and full‑year EPS forecasts (Q4‑2025 to Q4‑2026 around ($0.11)–($0.13); FY2026 at ($0.48)), notably better than the consensus FY2026 loss of ($1.22). The upgrade + tighter estimates support a re‑rating of the stock. MarketBeat IRD
• Positive Sentiment: Opus raised immediate capital via a $25M private placement: 7,374,632 shares of Series B Non‑Voting Convertible Preferred at $3.39 per share — provides cash to fund development and reduce near‑term financing risk, a common positive for clinical‑stage biotechs. GlobeNewswire Release MSN Coverage
• Neutral Sentiment: The financing was priced at $3.39 per preferred share and is non‑voting; official terms and conversion mechanics matter for modeling but the announcement itself is neutral-to-positive until conversion details are exercised. GlobeNewswire Release
• Negative Sentiment: Convertible preferreds can dilute common shareholders if converted; the $3.39 placement price is close to the recent trading level, so potential dilution and future overhang are real risks investors should model (impact depends on conversion rate and any anti‑dilution provisions). GlobeNewswire Release
• Negative Sentiment: Opus remains a loss‑making, clinical‑stage biotech with operational risk; consensus still projects negative EPS and high cash burn until clinical milestones or additional financing occur — keep monitoring cash runway and trial progress. MarketBeat IRD

Insider Activity

In other news, Director Cam Gallagher purchased 83,000 shares of Opus Genetics stock in a transaction on Monday, December 29th. The stock was purchased at an average price of $1.97 per share, with a total value of $163,510.00. Following the transaction, the director directly owned 83,000 shares in the company, valued at $163,510. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Fighting Blindness Foundation sold 4,000,000 shares of Opus Genetics stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $2.15, for a total transaction of $8,600,000.00. Following the completion of the sale, the director owned 5,492,171 shares in the company, valued at $11,808,167.65. This trade represents a 42.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 6.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of IRD. BIOS Capital Management LP raised its holdings in Opus Genetics by 270.1% in the 2nd quarter. BIOS Capital Management LP now owns 3,683,429 shares of the company’s stock valued at $3,462,000 after acquiring an additional 2,688,180 shares during the period. Nantahala Capital Management LLC grew its position in shares of Opus Genetics by 42.9% in the fourth quarter. Nantahala Capital Management LLC now owns 4,781,330 shares of the company’s stock valued at $9,610,000 after purchasing an additional 1,435,407 shares during the last quarter. Mink Brook Asset Management LLC grew its position in shares of Opus Genetics by 34.5% in the fourth quarter. Mink Brook Asset Management LLC now owns 1,665,631 shares of the company’s stock valued at $3,348,000 after purchasing an additional 427,684 shares during the last quarter. Voss Capital LP increased its stake in shares of Opus Genetics by 260.8% during the second quarter. Voss Capital LP now owns 541,159 shares of the company’s stock worth $510,000 after purchasing an additional 391,159 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in Opus Genetics by 35.3% during the 3rd quarter. Vanguard Group Inc. now owns 1,342,025 shares of the company’s stock worth $2,214,000 after purchasing an additional 349,825 shares during the last quarter. Institutional investors and hedge funds own 14.97% of the company’s stock.

Analyst Ratings Changes

IRD has been the topic of several analyst reports. Brookline Capital Acquisition upgraded Opus Genetics to a “strong-buy” rating in a report on Monday, December 1st. Lifesci Capital upgraded Opus Genetics to a “strong-buy” rating in a research note on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Opus Genetics in a report on Thursday, January 22nd. B. Riley Financial started coverage on shares of Opus Genetics in a report on Wednesday, December 10th. They set a “buy” rating and a $9.00 target price on the stock. Finally, Chardan Capital reaffirmed a “buy” rating and set a $9.00 price target on shares of Opus Genetics in a research report on Thursday, November 13th. Two analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $7.75.

Opus Genetics Stock Performance

Shares of IRD stock traded up $0.25 during trading on Friday, reaching $3.64. 797,531 shares of the company’s stock were exchanged, compared to its average volume of 1,089,146. Opus Genetics has a twelve month low of $0.65 and a twelve month high of $3.70. The firm’s fifty day moving average price is $2.36 and its 200-day moving average price is $1.90. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 0.18. The stock has a market capitalization of $251.01 million, a PE ratio of -1.94 and a beta of 0.58.

Opus Genetics (NASDAQ:IRD) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02. The firm had revenue of $3.08 million during the quarter, compared to analysts’ expectations of $3.07 million. Opus Genetics had a negative net margin of 466.09% and a negative return on equity of 697.94%. As a group, sell-side analysts anticipate that Opus Genetics will post -1.22 EPS for the current year.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.